Paratek Pharmaceuticals (Paratek Pharmaceuticals) 5-Year Dividend Growth Rate : 0.00% (As of Jun. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Paratek Pharmaceuticals 5-Year Dividend Growth Rate?

Paratek Pharmaceuticals's Dividends per Share for the three months ended in Jun. 2023 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Paratek Pharmaceuticals's Dividend Payout Ratio for the three months ended in Jun. 2023 was 0.00. As of today, Paratek Pharmaceuticals's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Paratek Pharmaceuticals's 5-Year Dividend Growth Rate

For the Biotechnology subindustry, Paratek Pharmaceuticals's 5-Year Dividend Growth Rate, along with its competitors' market caps and 5-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Paratek Pharmaceuticals's 5-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paratek Pharmaceuticals's 5-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Paratek Pharmaceuticals's 5-Year Dividend Growth Rate falls into.

Paratek Pharmaceuticals 5-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Paratek Pharmaceuticals (NAS:PRTK) 5-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Paratek Pharmaceuticals's Dividend Payout Ratio for the quarter that ended in Jun. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Jun. 2023 )	/	EPS without NRI (Q: Jun. 2023 )
	=	0	/	-0.25
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

During the past 13 years, the highest Dividend Yield of Paratek Pharmaceuticals was 69.99%. The lowest was 21.23%. And the median was 42.09%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paratek Pharmaceuticals 5-Year Dividend Growth Rate Related Terms

Thank you for viewing the detailed overview of Paratek Pharmaceuticals's 5-Year Dividend Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Paratek Pharmaceuticals (Paratek Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paratek Pharmaceuticals Inc (NAS:PRTK) » Definitions » 5-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

75 Park Plaza, 4th Floor, Boston, MA, USA, 02116

Website

https://www.paratekpharma.com

Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.

Executives

Minnie Baylor-henry	director	C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Kristine Peterson	director	AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355
Timothy R Franson	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Jeffrey Stein	director	6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Thomas John Dietz	director	C/O TRANSCEPT PHARMACEUTICAL, INC., 1003 W. CUTTING BLVD, STE 110, PT. RICHMOND CA 94804
Evan Loh	director, officer: CEO	75 KNEELAND STREET, BOSTON MA 02111
William M. Haskel	officer: CLO, General Counsel & Sec.	ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073
Adam Woodrow	officer: President & Chief Commercial	C/O PARATEK PHARMACEUTICALS, INC., 75 KNEELAND STREET, BOSTON MA 02111
Randall B. Brenner	officer: Chief Development & Regulatory	C/O PARATEK PHARMACEUTICALS, INC., 75 PARK PLAZA, 4TH FLOOR, BOSTON MA 02116
Robert S Radie	director	101 LINDENWOOD DRIVE, SUITE 225, MALVERN PA 19355
Rolf K Hoffmann	director	LORBEERWEG 7, WEGGIS V8 CH-6353
Michael Bigham	director, officer: Exec. Chairman of the Board	890 WINTER STREET, WALTHAM MA 02451
James D Dondero	10 percent owner	300 CRESCENT COURT, SUITE 700, DALLAS TX 75201
Douglas W. Pagan	officer: Chief Financial Officer	75 KNEELAND STREET, BOSTON MA 02111
Omega Fund Iv, L.p.	10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199